Literature DB >> 7719460

Determination of L-735 524, an human immunodeficiency virus protease inhibitor, in human plasma and urine via high-performance liquid chromatography with column switching.

E Woolf1, T Au, H Haddix, B Matuszewski.   

Abstract

A method for the determination of an HIV protease inhibitor, L-735 524, in human plasma and urine is described. Isolation of the analyte and the internal standard from the matrices was achieved via multiple liquid-liquid extractions with methyl tert.-butyl ether. The analyte lacks significant UV absorption at wavelengths greater than 220 nm, hence a column switching system using a cyano and C18 column was used to further purify the extracts prior to UV detection at 210 nm. The assay has been found to be linear and has been validated over the concentration range of 5 to 500 ng/ml, when 1-ml aliquots of plasma or urine were extracted. The assay has been utilized to support human pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7719460     DOI: 10.1016/0021-9673(94)00608-c

Source DB:  PubMed          Journal:  J Chromatogr A        ISSN: 0021-9673            Impact factor:   4.759


  7 in total

1.  Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture.

Authors:  M Nascimbeni; C Lamotte; G Peytavin; R Farinotti; F Clavel
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

2.  Lack of indinavir-associated nephrological complications in HIV-infected adults (predominantly women) with high indinavir plasma concentration in Abidjan, Côte d'Ivoire.

Authors:  Christine Danel; Raoul Moh; Gilles Peytavin; Amani Anzian; Albert Minga; Olivier Ba Gomis; Boga Seri; Gustave Nzunettu; Delphine Gabillard; Roger Salamon; Emmanuel Bissagnene; Xavier Anglaret
Journal:  AIDS Res Hum Retroviruses       Date:  2007-01       Impact factor: 2.205

3.  Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.

Authors:  B M Sadler; C Gillotin; Y Lou; J J Eron; W Lang; R Haubrich; D S Stein
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

4.  Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients.

Authors:  S De Wit; M Debier; M De Smet; J McCrea; J Stone; A Carides; C Matthews; P Deutsch; N Clumeck
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

5.  Single-dose pharmacokinetics of indinavir and the effect of food.

Authors:  K C Yeh; P J Deutsch; H Haddix; M Hesney; V Hoagland; W D Ju; S J Justice; B Osborne; A T Sterrett; J A Stone; E Woolf; S Waldman
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

6.  Indinavir Pharmacokinetics during Different Phases of the Menstrual Cycle in HIV-Infected Women.

Authors:  Charles E Frost; John Adams; Mark Shelton; Abdel-Hameed I Mohammed Ebid; Lawrence J Gugino; Ross Hewitt; Robin Difrancesco; Elizabeth Ingalls; Stephen Cousins; J Hu; Gene D Morse
Journal:  Clin Drug Investig       Date:  2002       Impact factor: 2.859

7.  Antiretroviral therapy with a twice-daily regimen containing 400 milligrams of indinavir and 100 milligrams of ritonavir in human immunodeficiency virus type 1-infected women during pregnancy.

Authors:  Jade Ghosn; Ines De Montgolfier; Chantal Cornélie; Stéphanie Dominguez; Claire Pérot; Gilles Peytavin; Anne-Geneviève Marcelin; Michèle Pauchard; Zineb Ouagari; Manuela Bonmarchand; Rachid Agher; Vincent Calvez; François Bricaire; Marc Dommergues; Christine Katlama; Roland Tubiana
Journal:  Antimicrob Agents Chemother       Date:  2008-02-04       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.